nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—osteoarthritis—Methylprednisolone—multiple sclerosis	0.267	0.5	CpDpCtD
Lidocaine—osteoarthritis—Prednisone—multiple sclerosis	0.267	0.5	CpDpCtD
Lidocaine—CYP2A6—Prednisolone—multiple sclerosis	0.0306	0.115	CbGbCtD
Lidocaine—CYP2D6—Fingolimod—multiple sclerosis	0.0233	0.0871	CbGbCtD
Lidocaine—CYP2A6—Dexamethasone—multiple sclerosis	0.018	0.0675	CbGbCtD
Lidocaine—ABCB1—Methylprednisolone—multiple sclerosis	0.0159	0.0596	CbGbCtD
Lidocaine—CYP3A4—Fingolimod—multiple sclerosis	0.0148	0.0554	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0123	0.0462	CbGbCtD
Lidocaine—CYP3A7—Dexamethasone—multiple sclerosis	0.0123	0.0462	CbGbCtD
Lidocaine—CYP2B6—Dexamethasone—multiple sclerosis	0.0117	0.044	CbGbCtD
Lidocaine—ABCB1—Mitoxantrone—multiple sclerosis	0.0116	0.0435	CbGbCtD
Lidocaine—ABCB1—Betamethasone—multiple sclerosis	0.0103	0.0387	CbGbCtD
Lidocaine—ABCB1—Prednisolone—multiple sclerosis	0.0102	0.0382	CbGbCtD
Lidocaine—ABCB1—Prednisone—multiple sclerosis	0.00964	0.0361	CbGbCtD
Lidocaine—CYP3A4—Methylprednisolone—multiple sclerosis	0.00953	0.0357	CbGbCtD
Lidocaine—CYP3A5—Dexamethasone—multiple sclerosis	0.00924	0.0346	CbGbCtD
Lidocaine—CYP2C8—Dexamethasone—multiple sclerosis	0.00889	0.0333	CbGbCtD
Lidocaine—SCN3A—spinal nerve—multiple sclerosis	0.00857	0.277	CbGeAlD
Lidocaine—CYP3A4—Triamcinolone—multiple sclerosis	0.00722	0.0271	CbGbCtD
Lidocaine—CYP3A4—Mitoxantrone—multiple sclerosis	0.00695	0.026	CbGbCtD
Lidocaine—CYP2C9—Dexamethasone—multiple sclerosis	0.0062	0.0232	CbGbCtD
Lidocaine—CYP3A4—Betamethasone—multiple sclerosis	0.0062	0.0232	CbGbCtD
Lidocaine—CYP3A4—Prednisolone—multiple sclerosis	0.00611	0.0229	CbGbCtD
Lidocaine—ABCB1—Dexamethasone—multiple sclerosis	0.00602	0.0225	CbGbCtD
Lidocaine—CYP3A4—Prednisone—multiple sclerosis	0.00577	0.0216	CbGbCtD
Lidocaine—CYP2D6—Dexamethasone—multiple sclerosis	0.00567	0.0212	CbGbCtD
Lidocaine—ABCB1—Methotrexate—multiple sclerosis	0.00483	0.0181	CbGbCtD
Lidocaine—CYP3A4—Dexamethasone—multiple sclerosis	0.0036	0.0135	CbGbCtD
Lidocaine—SCN10A—peripheral nervous system—multiple sclerosis	0.00232	0.0751	CbGeAlD
Lidocaine—SCN10A—nerve—multiple sclerosis	0.00181	0.0585	CbGeAlD
Lidocaine—SCN2A—brainstem—multiple sclerosis	0.000806	0.0261	CbGeAlD
Lidocaine—Chloroprocaine—BCHE—multiple sclerosis	0.000697	0.549	CrCbGaD
Lidocaine—SCN9A—midbrain—multiple sclerosis	0.000651	0.021	CbGeAlD
Lidocaine—SCN9A—spinal cord—multiple sclerosis	0.000635	0.0205	CbGeAlD
Lidocaine—EGFR—cerebellum—multiple sclerosis	0.000611	0.0198	CbGeAlD
Lidocaine—SCN2A—medulla oblongata—multiple sclerosis	0.000562	0.0182	CbGeAlD
Lidocaine—SCN2A—midbrain—multiple sclerosis	0.000514	0.0166	CbGeAlD
Lidocaine—SCN2A—spinal cord—multiple sclerosis	0.000501	0.0162	CbGeAlD
Lidocaine—EGFR—brain—multiple sclerosis	0.000496	0.0161	CbGeAlD
Lidocaine—SCN3A—medulla oblongata—multiple sclerosis	0.000494	0.016	CbGeAlD
Lidocaine—SCN10A—spinal cord—multiple sclerosis	0.000483	0.0156	CbGeAlD
Lidocaine—SCN4A—nervous system—multiple sclerosis	0.000477	0.0154	CbGeAlD
Lidocaine—SCN4A—central nervous system—multiple sclerosis	0.000459	0.0149	CbGeAlD
Lidocaine—SCN3A—midbrain—multiple sclerosis	0.000451	0.0146	CbGeAlD
Lidocaine—SCN3A—spinal cord—multiple sclerosis	0.00044	0.0142	CbGeAlD
Lidocaine—SCN2A—nervous system—multiple sclerosis	0.000422	0.0137	CbGeAlD
Lidocaine—SCN9A—brain—multiple sclerosis	0.000409	0.0132	CbGeAlD
Lidocaine—SCN10A—nervous system—multiple sclerosis	0.000407	0.0132	CbGeAlD
Lidocaine—SCN2A—central nervous system—multiple sclerosis	0.000407	0.0131	CbGeAlD
Lidocaine—SCN2A—cerebellum—multiple sclerosis	0.000397	0.0128	CbGeAlD
Lidocaine—SLC22A5—retina—multiple sclerosis	0.000396	0.0128	CbGeAlD
Lidocaine—SCN10A—central nervous system—multiple sclerosis	0.000392	0.0127	CbGeAlD
Lidocaine—SCN3A—nervous system—multiple sclerosis	0.000371	0.012	CbGeAlD
Lidocaine—SCN5A—nervous system—multiple sclerosis	0.00037	0.012	CbGeAlD
Lidocaine—SCN4A—brain—multiple sclerosis	0.000365	0.0118	CbGeAlD
Lidocaine—SCN3A—central nervous system—multiple sclerosis	0.000357	0.0116	CbGeAlD
Lidocaine—SCN5A—central nervous system—multiple sclerosis	0.000356	0.0115	CbGeAlD
Lidocaine—SCN3A—cerebellum—multiple sclerosis	0.000349	0.0113	CbGeAlD
Lidocaine—CYP2A6—cerebellum—multiple sclerosis	0.000349	0.0113	CbGeAlD
Lidocaine—Procainamide—BCHE—multiple sclerosis	0.000344	0.271	CrCbGaD
Lidocaine—SCN2A—brain—multiple sclerosis	0.000323	0.0104	CbGeAlD
Lidocaine—SCN10A—brain—multiple sclerosis	0.000311	0.0101	CbGeAlD
Lidocaine—SLC22A5—medulla oblongata—multiple sclerosis	0.000286	0.00925	CbGeAlD
Lidocaine—SCN3A—brain—multiple sclerosis	0.000284	0.00917	CbGeAlD
Lidocaine—CYP2A6—brain—multiple sclerosis	0.000283	0.00917	CbGeAlD
Lidocaine—SCN5A—brain—multiple sclerosis	0.000283	0.00915	CbGeAlD
Lidocaine—CYP2D6—brainstem—multiple sclerosis	0.000265	0.00856	CbGeAlD
Lidocaine—SLC22A5—midbrain—multiple sclerosis	0.000262	0.00846	CbGeAlD
Lidocaine—SLC22A5—spinal cord—multiple sclerosis	0.000255	0.00825	CbGeAlD
Lidocaine—Tocainide—ALB—multiple sclerosis	0.000229	0.18	CrCbGaD
Lidocaine—SLC22A5—cerebellum—multiple sclerosis	0.000202	0.00654	CbGeAlD
Lidocaine—CYP2B6—nervous system—multiple sclerosis	0.000187	0.00604	CbGeAlD
Lidocaine—ABCB1—retina—multiple sclerosis	0.000184	0.00594	CbGeAlD
Lidocaine—CYP2B6—central nervous system—multiple sclerosis	0.00018	0.00581	CbGeAlD
Lidocaine—SLC22A5—brain—multiple sclerosis	0.000164	0.00531	CbGeAlD
Lidocaine—CYP2C8—brain—multiple sclerosis	0.000159	0.00515	CbGeAlD
Lidocaine—Haemoglobin—Triamcinolone—multiple sclerosis	0.000154	0.00143	CcSEcCtD
Lidocaine—Haemoglobin—Methylprednisolone—multiple sclerosis	0.000153	0.00143	CcSEcCtD
Lidocaine—Rhinitis—Triamcinolone—multiple sclerosis	0.000153	0.00143	CcSEcCtD
Lidocaine—Rhinitis—Methylprednisolone—multiple sclerosis	0.000153	0.00143	CcSEcCtD
Lidocaine—Haemorrhage—Triamcinolone—multiple sclerosis	0.000153	0.00143	CcSEcCtD
Lidocaine—Convulsion—Mitoxantrone—multiple sclerosis	0.000153	0.00143	CcSEcCtD
Lidocaine—Haemorrhage—Methylprednisolone—multiple sclerosis	0.000152	0.00142	CcSEcCtD
Lidocaine—Hypertension—Mitoxantrone—multiple sclerosis	0.000152	0.00142	CcSEcCtD
Lidocaine—Neuropathy peripheral—Dexamethasone—multiple sclerosis	0.000151	0.00141	CcSEcCtD
Lidocaine—Neuropathy peripheral—Betamethasone—multiple sclerosis	0.000151	0.00141	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Methotrexate—multiple sclerosis	0.000151	0.00141	CcSEcCtD
Lidocaine—Chest pain—Mitoxantrone—multiple sclerosis	0.00015	0.0014	CcSEcCtD
Lidocaine—Anxiety—Mitoxantrone—multiple sclerosis	0.00015	0.0014	CcSEcCtD
Lidocaine—Sweating increased—Prednisone—multiple sclerosis	0.000147	0.00137	CcSEcCtD
Lidocaine—Visual impairment—Methylprednisolone—multiple sclerosis	0.000147	0.00137	CcSEcCtD
Lidocaine—Feeling abnormal—Azathioprine—multiple sclerosis	0.000147	0.00137	CcSEcCtD
Lidocaine—Osteoarthritis—Methotrexate—multiple sclerosis	0.000146	0.00136	CcSEcCtD
Lidocaine—Confusional state—Mitoxantrone—multiple sclerosis	0.000145	0.00136	CcSEcCtD
Lidocaine—Dizziness—Cladribine—multiple sclerosis	0.000145	0.00135	CcSEcCtD
Lidocaine—Erythema—Prednisolone—multiple sclerosis	0.000145	0.00135	CcSEcCtD
Lidocaine—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000144	0.00134	CcSEcCtD
Lidocaine—Oedema—Mitoxantrone—multiple sclerosis	0.000144	0.00134	CcSEcCtD
Lidocaine—CYP2B6—brain—multiple sclerosis	0.000143	0.00462	CbGeAlD
Lidocaine—Eye disorder—Methylprednisolone—multiple sclerosis	0.000142	0.00133	CcSEcCtD
Lidocaine—Shock—Mitoxantrone—multiple sclerosis	0.000142	0.00132	CcSEcCtD
Lidocaine—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000141	0.00132	CcSEcCtD
Lidocaine—Bradycardia—Dexamethasone—multiple sclerosis	0.000141	0.00132	CcSEcCtD
Lidocaine—Bradycardia—Betamethasone—multiple sclerosis	0.000141	0.00132	CcSEcCtD
Lidocaine—CYP3A4—nervous system—multiple sclerosis	0.000141	0.00456	CbGeAlD
Lidocaine—Haemoglobin—Betamethasone—multiple sclerosis	0.000139	0.0013	CcSEcCtD
Lidocaine—Haemoglobin—Dexamethasone—multiple sclerosis	0.000139	0.0013	CcSEcCtD
Lidocaine—Vomiting—Cladribine—multiple sclerosis	0.000139	0.0013	CcSEcCtD
Lidocaine—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000139	0.0013	CcSEcCtD
Lidocaine—CYP2D6—nervous system—multiple sclerosis	0.000139	0.00449	CbGeAlD
Lidocaine—Haemorrhage—Betamethasone—multiple sclerosis	0.000139	0.0013	CcSEcCtD
Lidocaine—Haemorrhage—Dexamethasone—multiple sclerosis	0.000139	0.0013	CcSEcCtD
Lidocaine—Angiopathy—Methylprednisolone—multiple sclerosis	0.000138	0.00129	CcSEcCtD
Lidocaine—Rash—Cladribine—multiple sclerosis	0.000138	0.00129	CcSEcCtD
Lidocaine—Dermatitis—Cladribine—multiple sclerosis	0.000138	0.00129	CcSEcCtD
Lidocaine—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000138	0.00129	CcSEcCtD
Lidocaine—Headache—Cladribine—multiple sclerosis	0.000137	0.00128	CcSEcCtD
Lidocaine—Vision blurred—Prednisolone—multiple sclerosis	0.000136	0.00127	CcSEcCtD
Lidocaine—CYP3A4—central nervous system—multiple sclerosis	0.000136	0.00439	CbGeAlD
Lidocaine—Hypotension—Mitoxantrone—multiple sclerosis	0.000134	0.00126	CcSEcCtD
Lidocaine—CYP2D6—central nervous system—multiple sclerosis	0.000134	0.00432	CbGeAlD
Lidocaine—Visual impairment—Dexamethasone—multiple sclerosis	0.000134	0.00125	CcSEcCtD
Lidocaine—Visual impairment—Betamethasone—multiple sclerosis	0.000134	0.00125	CcSEcCtD
Lidocaine—Erythema—Triamcinolone—multiple sclerosis	0.000133	0.00124	CcSEcCtD
Lidocaine—ABCB1—medulla oblongata—multiple sclerosis	0.000133	0.0043	CbGeAlD
Lidocaine—Erythema—Methylprednisolone—multiple sclerosis	0.000133	0.00124	CcSEcCtD
Lidocaine—Angioedema—Prednisolone—multiple sclerosis	0.000132	0.00123	CcSEcCtD
Lidocaine—Neuropathy peripheral—Prednisone—multiple sclerosis	0.000132	0.00123	CcSEcCtD
Lidocaine—Hypersensitivity—Azathioprine—multiple sclerosis	0.000131	0.00123	CcSEcCtD
Lidocaine—CYP2D6—cerebellum—multiple sclerosis	0.000131	0.00422	CbGeAlD
Lidocaine—Dysgeusia—Triamcinolone—multiple sclerosis	0.00013	0.00122	CcSEcCtD
Lidocaine—Nausea—Cladribine—multiple sclerosis	0.00013	0.00121	CcSEcCtD
Lidocaine—Eye disorder—Dexamethasone—multiple sclerosis	0.00013	0.00121	CcSEcCtD
Lidocaine—Eye disorder—Betamethasone—multiple sclerosis	0.00013	0.00121	CcSEcCtD
Lidocaine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000129	0.00121	CcSEcCtD
Lidocaine—Back pain—Triamcinolone—multiple sclerosis	0.000129	0.0012	CcSEcCtD
Lidocaine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000128	0.0012	CcSEcCtD
Lidocaine—Somnolence—Mitoxantrone—multiple sclerosis	0.000128	0.00119	CcSEcCtD
Lidocaine—Loss of consciousness—Prednisolone—multiple sclerosis	0.000127	0.00119	CcSEcCtD
Lidocaine—Asthma—Methotrexate—multiple sclerosis	0.000126	0.00118	CcSEcCtD
Lidocaine—Angiopathy—Dexamethasone—multiple sclerosis	0.000126	0.00118	CcSEcCtD
Lidocaine—Angiopathy—Betamethasone—multiple sclerosis	0.000126	0.00118	CcSEcCtD
Lidocaine—Convulsion—Prednisolone—multiple sclerosis	0.000125	0.00117	CcSEcCtD
Lidocaine—Hypertension—Prednisolone—multiple sclerosis	0.000125	0.00117	CcSEcCtD
Lidocaine—Pain—Mitoxantrone—multiple sclerosis	0.000123	0.00115	CcSEcCtD
Lidocaine—Bradycardia—Prednisone—multiple sclerosis	0.000123	0.00115	CcSEcCtD
Lidocaine—Angioedema—Triamcinolone—multiple sclerosis	0.000122	0.00114	CcSEcCtD
Lidocaine—ABCB1—midbrain—multiple sclerosis	0.000121	0.00393	CbGeAlD
Lidocaine—Haemoglobin—Prednisone—multiple sclerosis	0.000121	0.00113	CcSEcCtD
Lidocaine—Angioedema—Methylprednisolone—multiple sclerosis	0.000121	0.00113	CcSEcCtD
Lidocaine—Haemorrhage—Prednisone—multiple sclerosis	0.000121	0.00113	CcSEcCtD
Lidocaine—Erythema—Dexamethasone—multiple sclerosis	0.000121	0.00113	CcSEcCtD
Lidocaine—Erythema—Betamethasone—multiple sclerosis	0.000121	0.00113	CcSEcCtD
Lidocaine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000119	0.00111	CcSEcCtD
Lidocaine—ABCB1—spinal cord—multiple sclerosis	0.000118	0.00383	CbGeAlD
Lidocaine—Oedema—Prednisolone—multiple sclerosis	0.000118	0.0011	CcSEcCtD
Lidocaine—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000118	0.0011	CcSEcCtD
Lidocaine—Dizziness—Azathioprine—multiple sclerosis	0.000118	0.0011	CcSEcCtD
Lidocaine—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000117	0.00109	CcSEcCtD
Lidocaine—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000117	0.00109	CcSEcCtD
Lidocaine—Shock—Prednisolone—multiple sclerosis	0.000116	0.00108	CcSEcCtD
Lidocaine—Convulsion—Triamcinolone—multiple sclerosis	0.000115	0.00108	CcSEcCtD
Lidocaine—Convulsion—Methylprednisolone—multiple sclerosis	0.000115	0.00107	CcSEcCtD
Lidocaine—Hypertension—Triamcinolone—multiple sclerosis	0.000115	0.00107	CcSEcCtD
Lidocaine—Hypertension—Methylprednisolone—multiple sclerosis	0.000115	0.00107	CcSEcCtD
Lidocaine—Urticaria—Mitoxantrone—multiple sclerosis	0.000114	0.00107	CcSEcCtD
Lidocaine—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000114	0.00107	CcSEcCtD
Lidocaine—Vomiting—Azathioprine—multiple sclerosis	0.000113	0.00106	CcSEcCtD
Lidocaine—Eye disorder—Prednisone—multiple sclerosis	0.000113	0.00105	CcSEcCtD
Lidocaine—Anxiety—Methylprednisolone—multiple sclerosis	0.000113	0.00105	CcSEcCtD
Lidocaine—Drowsiness—Methotrexate—multiple sclerosis	0.000112	0.00105	CcSEcCtD
Lidocaine—Rash—Azathioprine—multiple sclerosis	0.000112	0.00105	CcSEcCtD
Lidocaine—Dermatitis—Azathioprine—multiple sclerosis	0.000112	0.00105	CcSEcCtD
Lidocaine—Flushing—Prednisone—multiple sclerosis	0.000112	0.00105	CcSEcCtD
Lidocaine—Headache—Azathioprine—multiple sclerosis	0.000111	0.00104	CcSEcCtD
Lidocaine—Angioedema—Betamethasone—multiple sclerosis	0.00011	0.00103	CcSEcCtD
Lidocaine—Angioedema—Dexamethasone—multiple sclerosis	0.00011	0.00103	CcSEcCtD
Lidocaine—Stomatitis—Methotrexate—multiple sclerosis	0.00011	0.00102	CcSEcCtD
Lidocaine—Angiopathy—Prednisone—multiple sclerosis	0.00011	0.00102	CcSEcCtD
Lidocaine—Confusional state—Methylprednisolone—multiple sclerosis	0.000109	0.00102	CcSEcCtD
Lidocaine—Immune system disorder—Prednisone—multiple sclerosis	0.000109	0.00102	CcSEcCtD
Lidocaine—Oedema—Triamcinolone—multiple sclerosis	0.000109	0.00101	CcSEcCtD
Lidocaine—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000109	0.00101	CcSEcCtD
Lidocaine—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000108	0.00101	CcSEcCtD
Lidocaine—Shock—Triamcinolone—multiple sclerosis	0.000107	0.000998	CcSEcCtD
Lidocaine—Shock—Methylprednisolone—multiple sclerosis	0.000107	0.000996	CcSEcCtD
Lidocaine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000106	0.000992	CcSEcCtD
Lidocaine—CYP2D6—brain—multiple sclerosis	0.000106	0.00343	CbGeAlD
Lidocaine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000106	0.000991	CcSEcCtD
Lidocaine—Loss of consciousness—Betamethasone—multiple sclerosis	0.000106	0.000991	CcSEcCtD
Lidocaine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000106	0.00099	CcSEcCtD
Lidocaine—Paraesthesia—Prednisolone—multiple sclerosis	0.000106	0.00099	CcSEcCtD
Lidocaine—Nausea—Azathioprine—multiple sclerosis	0.000106	0.000988	CcSEcCtD
Lidocaine—Erythema—Prednisone—multiple sclerosis	0.000105	0.000982	CcSEcCtD
Lidocaine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000105	0.00098	CcSEcCtD
Lidocaine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000105	0.000978	CcSEcCtD
Lidocaine—Convulsion—Dexamethasone—multiple sclerosis	0.000105	0.000977	CcSEcCtD
Lidocaine—Convulsion—Betamethasone—multiple sclerosis	0.000105	0.000977	CcSEcCtD
Lidocaine—Hypertension—Dexamethasone—multiple sclerosis	0.000104	0.000973	CcSEcCtD
Lidocaine—Hypertension—Betamethasone—multiple sclerosis	0.000104	0.000973	CcSEcCtD
Lidocaine—Asthenia—Mitoxantrone—multiple sclerosis	0.000103	0.000964	CcSEcCtD
Lidocaine—Anxiety—Dexamethasone—multiple sclerosis	0.000102	0.000957	CcSEcCtD
Lidocaine—Anxiety—Betamethasone—multiple sclerosis	0.000102	0.000957	CcSEcCtD
Lidocaine—Haemoglobin—Methotrexate—multiple sclerosis	0.000101	0.000947	CcSEcCtD
Lidocaine—Hypotension—Methylprednisolone—multiple sclerosis	0.000101	0.000946	CcSEcCtD
Lidocaine—Pain—Prednisolone—multiple sclerosis	0.000101	0.000943	CcSEcCtD
Lidocaine—Haemorrhage—Methotrexate—multiple sclerosis	0.000101	0.000943	CcSEcCtD
Lidocaine—ABCB1—nervous system—multiple sclerosis	9.98e-05	0.00323	CbGeAlD
Lidocaine—Vision blurred—Prednisone—multiple sclerosis	9.9e-05	0.000925	CcSEcCtD
Lidocaine—Oedema—Betamethasone—multiple sclerosis	9.85e-05	0.00092	CcSEcCtD
Lidocaine—Anaphylactic shock—Dexamethasone—multiple sclerosis	9.85e-05	0.00092	CcSEcCtD
Lidocaine—Anaphylactic shock—Betamethasone—multiple sclerosis	9.85e-05	0.00092	CcSEcCtD
Lidocaine—Oedema—Dexamethasone—multiple sclerosis	9.85e-05	0.00092	CcSEcCtD
Lidocaine—Paraesthesia—Triamcinolone—multiple sclerosis	9.75e-05	0.000911	CcSEcCtD
Lidocaine—Feeling abnormal—Prednisolone—multiple sclerosis	9.73e-05	0.000909	CcSEcCtD
Lidocaine—Paraesthesia—Methylprednisolone—multiple sclerosis	9.72e-05	0.000909	CcSEcCtD
Lidocaine—Visual impairment—Methotrexate—multiple sclerosis	9.72e-05	0.000908	CcSEcCtD
Lidocaine—Shock—Dexamethasone—multiple sclerosis	9.69e-05	0.000905	CcSEcCtD
Lidocaine—Shock—Betamethasone—multiple sclerosis	9.69e-05	0.000905	CcSEcCtD
Lidocaine—Dyspnoea—Triamcinolone—multiple sclerosis	9.68e-05	0.000904	CcSEcCtD
Lidocaine—Nervous system disorder—Dexamethasone—multiple sclerosis	9.66e-05	0.000902	CcSEcCtD
Lidocaine—Nervous system disorder—Betamethasone—multiple sclerosis	9.66e-05	0.000902	CcSEcCtD
Lidocaine—Agitation—Prednisone—multiple sclerosis	9.66e-05	0.000902	CcSEcCtD
Lidocaine—ABCB1—central nervous system—multiple sclerosis	9.61e-05	0.00311	CbGeAlD
Lidocaine—Angioedema—Prednisone—multiple sclerosis	9.6e-05	0.000897	CcSEcCtD
Lidocaine—Hyperhidrosis—Dexamethasone—multiple sclerosis	9.52e-05	0.00089	CcSEcCtD
Lidocaine—Hyperhidrosis—Betamethasone—multiple sclerosis	9.52e-05	0.00089	CcSEcCtD
Lidocaine—Eye disorder—Methotrexate—multiple sclerosis	9.43e-05	0.000881	CcSEcCtD
Lidocaine—Tinnitus—Methotrexate—multiple sclerosis	9.41e-05	0.000879	CcSEcCtD
Lidocaine—ABCB1—cerebellum—multiple sclerosis	9.39e-05	0.00304	CbGeAlD
Lidocaine—Urticaria—Prednisolone—multiple sclerosis	9.38e-05	0.000876	CcSEcCtD
Lidocaine—Cardiac disorder—Methotrexate—multiple sclerosis	9.36e-05	0.000875	CcSEcCtD
Lidocaine—Pain—Triamcinolone—multiple sclerosis	9.28e-05	0.000867	CcSEcCtD
Lidocaine—Loss of consciousness—Prednisone—multiple sclerosis	9.24e-05	0.000863	CcSEcCtD
Lidocaine—Hypotension—Dexamethasone—multiple sclerosis	9.2e-05	0.00086	CcSEcCtD
Lidocaine—Hypotension—Betamethasone—multiple sclerosis	9.2e-05	0.00086	CcSEcCtD
Lidocaine—Angiopathy—Methotrexate—multiple sclerosis	9.15e-05	0.000855	CcSEcCtD
Lidocaine—Vomiting—Mitoxantrone—multiple sclerosis	9.15e-05	0.000855	CcSEcCtD
Lidocaine—Immune system disorder—Methotrexate—multiple sclerosis	9.11e-05	0.000851	CcSEcCtD
Lidocaine—Convulsion—Prednisone—multiple sclerosis	9.1e-05	0.000851	CcSEcCtD
Lidocaine—Hypertension—Prednisone—multiple sclerosis	9.07e-05	0.000848	CcSEcCtD
Lidocaine—Rash—Mitoxantrone—multiple sclerosis	9.07e-05	0.000848	CcSEcCtD
Lidocaine—Dermatitis—Mitoxantrone—multiple sclerosis	9.06e-05	0.000847	CcSEcCtD
Lidocaine—Chills—Methotrexate—multiple sclerosis	9.05e-05	0.000846	CcSEcCtD
Lidocaine—Headache—Mitoxantrone—multiple sclerosis	9.01e-05	0.000842	CcSEcCtD
Lidocaine—Feeling abnormal—Triamcinolone—multiple sclerosis	8.94e-05	0.000836	CcSEcCtD
Lidocaine—Feeling abnormal—Methylprednisolone—multiple sclerosis	8.92e-05	0.000834	CcSEcCtD
Lidocaine—Anxiety—Prednisone—multiple sclerosis	8.91e-05	0.000833	CcSEcCtD
Lidocaine—Paraesthesia—Dexamethasone—multiple sclerosis	8.84e-05	0.000826	CcSEcCtD
Lidocaine—Paraesthesia—Betamethasone—multiple sclerosis	8.84e-05	0.000826	CcSEcCtD
Lidocaine—Erythema—Methotrexate—multiple sclerosis	8.78e-05	0.000821	CcSEcCtD
Lidocaine—Hypersensitivity—Prednisolone—multiple sclerosis	8.69e-05	0.000812	CcSEcCtD
Lidocaine—Urticaria—Triamcinolone—multiple sclerosis	8.62e-05	0.000806	CcSEcCtD
Lidocaine—Urticaria—Methylprednisolone—multiple sclerosis	8.6e-05	0.000804	CcSEcCtD
Lidocaine—Dysgeusia—Methotrexate—multiple sclerosis	8.6e-05	0.000804	CcSEcCtD
Lidocaine—Anaphylactic shock—Prednisone—multiple sclerosis	8.58e-05	0.000801	CcSEcCtD
Lidocaine—Oedema—Prednisone—multiple sclerosis	8.58e-05	0.000801	CcSEcCtD
Lidocaine—Nausea—Mitoxantrone—multiple sclerosis	8.54e-05	0.000798	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	8.5e-05	0.000794	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	8.5e-05	0.000794	CcSEcCtD
Lidocaine—Back pain—Methotrexate—multiple sclerosis	8.49e-05	0.000794	CcSEcCtD
Lidocaine—Shock—Prednisone—multiple sclerosis	8.44e-05	0.000788	CcSEcCtD
Lidocaine—Pain—Betamethasone—multiple sclerosis	8.42e-05	0.000787	CcSEcCtD
Lidocaine—Pain—Dexamethasone—multiple sclerosis	8.42e-05	0.000787	CcSEcCtD
Lidocaine—Nervous system disorder—Prednisone—multiple sclerosis	8.41e-05	0.000786	CcSEcCtD
Lidocaine—Hyperhidrosis—Prednisone—multiple sclerosis	8.29e-05	0.000775	CcSEcCtD
Lidocaine—Vision blurred—Methotrexate—multiple sclerosis	8.28e-05	0.000773	CcSEcCtD
Lidocaine—Feeling abnormal—Betamethasone—multiple sclerosis	8.11e-05	0.000758	CcSEcCtD
Lidocaine—Feeling abnormal—Dexamethasone—multiple sclerosis	8.11e-05	0.000758	CcSEcCtD
Lidocaine—Hypersensitivity—Triamcinolone—multiple sclerosis	8e-05	0.000747	CcSEcCtD
Lidocaine—Hypersensitivity—Methylprednisolone—multiple sclerosis	7.98e-05	0.000746	CcSEcCtD
Lidocaine—Urticaria—Dexamethasone—multiple sclerosis	7.82e-05	0.000731	CcSEcCtD
Lidocaine—Urticaria—Betamethasone—multiple sclerosis	7.82e-05	0.000731	CcSEcCtD
Lidocaine—Dizziness—Prednisolone—multiple sclerosis	7.8e-05	0.000729	CcSEcCtD
Lidocaine—Asthenia—Triamcinolone—multiple sclerosis	7.79e-05	0.000728	CcSEcCtD
Lidocaine—Asthenia—Methylprednisolone—multiple sclerosis	7.77e-05	0.000726	CcSEcCtD
Lidocaine—Paraesthesia—Prednisone—multiple sclerosis	7.7e-05	0.00072	CcSEcCtD
Lidocaine—ABCB1—brain—multiple sclerosis	7.63e-05	0.00247	CbGeAlD
Lidocaine—Convulsion—Methotrexate—multiple sclerosis	7.61e-05	0.000711	CcSEcCtD
Lidocaine—Chest pain—Methotrexate—multiple sclerosis	7.48e-05	0.000699	CcSEcCtD
Lidocaine—Rash—Prednisolone—multiple sclerosis	7.44e-05	0.000695	CcSEcCtD
Lidocaine—Dermatitis—Prednisolone—multiple sclerosis	7.43e-05	0.000695	CcSEcCtD
Lidocaine—Headache—Prednisolone—multiple sclerosis	7.39e-05	0.000691	CcSEcCtD
Lidocaine—Confusional state—Methotrexate—multiple sclerosis	7.23e-05	0.000675	CcSEcCtD
Lidocaine—Dizziness—Triamcinolone—multiple sclerosis	7.18e-05	0.000671	CcSEcCtD
Lidocaine—Anaphylactic shock—Methotrexate—multiple sclerosis	7.17e-05	0.00067	CcSEcCtD
Lidocaine—Dizziness—Methylprednisolone—multiple sclerosis	7.16e-05	0.000669	CcSEcCtD
Lidocaine—Feeling abnormal—Prednisone—multiple sclerosis	7.07e-05	0.00066	CcSEcCtD
Lidocaine—Asthenia—Betamethasone—multiple sclerosis	7.07e-05	0.00066	CcSEcCtD
Lidocaine—Asthenia—Dexamethasone—multiple sclerosis	7.07e-05	0.00066	CcSEcCtD
Lidocaine—Nervous system disorder—Methotrexate—multiple sclerosis	7.03e-05	0.000657	CcSEcCtD
Lidocaine—Nausea—Prednisolone—multiple sclerosis	7.01e-05	0.000655	CcSEcCtD
Lidocaine—Hyperhidrosis—Methotrexate—multiple sclerosis	6.93e-05	0.000647	CcSEcCtD
Lidocaine—Vomiting—Triamcinolone—multiple sclerosis	6.9e-05	0.000645	CcSEcCtD
Lidocaine—Vomiting—Methylprednisolone—multiple sclerosis	6.89e-05	0.000643	CcSEcCtD
Lidocaine—Rash—Triamcinolone—multiple sclerosis	6.84e-05	0.000639	CcSEcCtD
Lidocaine—Dermatitis—Triamcinolone—multiple sclerosis	6.84e-05	0.000639	CcSEcCtD
Lidocaine—Rash—Methylprednisolone—multiple sclerosis	6.83e-05	0.000638	CcSEcCtD
Lidocaine—Dermatitis—Methylprednisolone—multiple sclerosis	6.82e-05	0.000637	CcSEcCtD
Lidocaine—Urticaria—Prednisone—multiple sclerosis	6.81e-05	0.000637	CcSEcCtD
Lidocaine—Headache—Triamcinolone—multiple sclerosis	6.8e-05	0.000635	CcSEcCtD
Lidocaine—Headache—Methylprednisolone—multiple sclerosis	6.78e-05	0.000634	CcSEcCtD
Lidocaine—Hypotension—Methotrexate—multiple sclerosis	6.7e-05	0.000626	CcSEcCtD
Lidocaine—Dizziness—Dexamethasone—multiple sclerosis	6.51e-05	0.000608	CcSEcCtD
Lidocaine—Dizziness—Betamethasone—multiple sclerosis	6.51e-05	0.000608	CcSEcCtD
Lidocaine—Nausea—Triamcinolone—multiple sclerosis	6.45e-05	0.000602	CcSEcCtD
Lidocaine—Paraesthesia—Methotrexate—multiple sclerosis	6.44e-05	0.000601	CcSEcCtD
Lidocaine—Nausea—Methylprednisolone—multiple sclerosis	6.43e-05	0.000601	CcSEcCtD
Lidocaine—Dyspnoea—Methotrexate—multiple sclerosis	6.39e-05	0.000597	CcSEcCtD
Lidocaine—Somnolence—Methotrexate—multiple sclerosis	6.37e-05	0.000595	CcSEcCtD
Lidocaine—Hypersensitivity—Prednisone—multiple sclerosis	6.32e-05	0.00059	CcSEcCtD
Lidocaine—Vomiting—Dexamethasone—multiple sclerosis	6.26e-05	0.000585	CcSEcCtD
Lidocaine—Vomiting—Betamethasone—multiple sclerosis	6.26e-05	0.000585	CcSEcCtD
Lidocaine—Rash—Betamethasone—multiple sclerosis	6.21e-05	0.00058	CcSEcCtD
Lidocaine—Rash—Dexamethasone—multiple sclerosis	6.21e-05	0.00058	CcSEcCtD
Lidocaine—Dermatitis—Betamethasone—multiple sclerosis	6.2e-05	0.00058	CcSEcCtD
Lidocaine—Dermatitis—Dexamethasone—multiple sclerosis	6.2e-05	0.00058	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	6.19e-05	0.000578	CcSEcCtD
Lidocaine—Headache—Betamethasone—multiple sclerosis	6.17e-05	0.000576	CcSEcCtD
Lidocaine—Headache—Dexamethasone—multiple sclerosis	6.17e-05	0.000576	CcSEcCtD
Lidocaine—Asthenia—Prednisone—multiple sclerosis	6.15e-05	0.000575	CcSEcCtD
Lidocaine—Pain—Methotrexate—multiple sclerosis	6.13e-05	0.000573	CcSEcCtD
Lidocaine—Feeling abnormal—Methotrexate—multiple sclerosis	5.91e-05	0.000552	CcSEcCtD
Lidocaine—Nausea—Betamethasone—multiple sclerosis	5.85e-05	0.000547	CcSEcCtD
Lidocaine—Nausea—Dexamethasone—multiple sclerosis	5.85e-05	0.000547	CcSEcCtD
Lidocaine—Urticaria—Methotrexate—multiple sclerosis	5.69e-05	0.000532	CcSEcCtD
Lidocaine—Dizziness—Prednisone—multiple sclerosis	5.67e-05	0.00053	CcSEcCtD
Lidocaine—Vomiting—Prednisone—multiple sclerosis	5.45e-05	0.00051	CcSEcCtD
Lidocaine—Rash—Prednisone—multiple sclerosis	5.41e-05	0.000505	CcSEcCtD
Lidocaine—Dermatitis—Prednisone—multiple sclerosis	5.4e-05	0.000505	CcSEcCtD
Lidocaine—Headache—Prednisone—multiple sclerosis	5.37e-05	0.000502	CcSEcCtD
Lidocaine—Hypersensitivity—Methotrexate—multiple sclerosis	5.28e-05	0.000493	CcSEcCtD
Lidocaine—Asthenia—Methotrexate—multiple sclerosis	5.14e-05	0.000481	CcSEcCtD
Lidocaine—Nausea—Prednisone—multiple sclerosis	5.09e-05	0.000476	CcSEcCtD
Lidocaine—Dizziness—Methotrexate—multiple sclerosis	4.74e-05	0.000443	CcSEcCtD
Lidocaine—Vomiting—Methotrexate—multiple sclerosis	4.56e-05	0.000426	CcSEcCtD
Lidocaine—Rash—Methotrexate—multiple sclerosis	4.52e-05	0.000422	CcSEcCtD
Lidocaine—Dermatitis—Methotrexate—multiple sclerosis	4.51e-05	0.000422	CcSEcCtD
Lidocaine—Headache—Methotrexate—multiple sclerosis	4.49e-05	0.00042	CcSEcCtD
Lidocaine—Nausea—Methotrexate—multiple sclerosis	4.26e-05	0.000398	CcSEcCtD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.78e-05	0.000297	CbGpPWpGaD
Lidocaine—EGFR—Disease—SLC11A1—multiple sclerosis	1.77e-05	0.000296	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CD40LG—multiple sclerosis	1.77e-05	0.000295	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—SRM—multiple sclerosis	1.76e-05	0.000293	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PTGER4—multiple sclerosis	1.75e-05	0.000292	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—HLA-B—multiple sclerosis	1.75e-05	0.000292	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CD8A—multiple sclerosis	1.75e-05	0.000292	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—IL6—multiple sclerosis	1.74e-05	0.000291	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—SRM—multiple sclerosis	1.74e-05	0.000291	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	1.74e-05	0.000291	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	1.74e-05	0.000291	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—RGS1—multiple sclerosis	1.74e-05	0.000291	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—TNF—multiple sclerosis	1.73e-05	0.00029	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—TNF—multiple sclerosis	1.72e-05	0.000288	CbGpPWpGaD
Lidocaine—EGFR—Immune System—TNFAIP3—multiple sclerosis	1.7e-05	0.000284	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.7e-05	0.000283	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CXCR3—multiple sclerosis	1.69e-05	0.000282	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HLA-B—multiple sclerosis	1.68e-05	0.000281	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—MAPK1—multiple sclerosis	1.68e-05	0.00028	CbGpPWpGaD
Lidocaine—SLC22A5—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.67e-05	0.000279	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—RRM1—multiple sclerosis	1.67e-05	0.000279	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—IL6—multiple sclerosis	1.67e-05	0.000279	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—GPR65—multiple sclerosis	1.65e-05	0.000275	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CCR2—multiple sclerosis	1.65e-05	0.000275	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—IL6—multiple sclerosis	1.64e-05	0.000274	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GPC5—multiple sclerosis	1.63e-05	0.000272	CbGpPWpGaD
Lidocaine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	1.63e-05	0.000272	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	1.62e-05	0.00027	CbGpPWpGaD
Lidocaine—CYP2C9—Biological oxidations—POMC—multiple sclerosis	1.61e-05	0.00027	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.6e-05	0.000267	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GPC5—multiple sclerosis	1.59e-05	0.000266	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—BCHE—multiple sclerosis	1.58e-05	0.000263	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—MMP9—multiple sclerosis	1.57e-05	0.000263	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—IL6—multiple sclerosis	1.57e-05	0.000262	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—IL6—multiple sclerosis	1.57e-05	0.000262	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—IL6—multiple sclerosis	1.56e-05	0.000261	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HLA-A—multiple sclerosis	1.56e-05	0.00026	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—IL6—multiple sclerosis	1.55e-05	0.000259	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—IL6—multiple sclerosis	1.55e-05	0.000258	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD28—multiple sclerosis	1.53e-05	0.000256	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CNR1—multiple sclerosis	1.52e-05	0.000254	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCR1—multiple sclerosis	1.51e-05	0.000252	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCL13—multiple sclerosis	1.51e-05	0.000252	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	1.51e-05	0.000252	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	1.51e-05	0.000252	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CCR2—multiple sclerosis	1.5e-05	0.000251	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PTPRC—multiple sclerosis	1.5e-05	0.000251	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—IL6—multiple sclerosis	1.5e-05	0.00025	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SRM—multiple sclerosis	1.49e-05	0.000249	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—TLR4—multiple sclerosis	1.48e-05	0.000248	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.47e-05	0.000246	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—IL6—multiple sclerosis	1.45e-05	0.000243	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—IL6—multiple sclerosis	1.45e-05	0.000243	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	1.45e-05	0.000243	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-DPB1—multiple sclerosis	1.45e-05	0.000243	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—MMP9—multiple sclerosis	1.44e-05	0.000241	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—IL6—multiple sclerosis	1.44e-05	0.000241	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—IL6—multiple sclerosis	1.44e-05	0.000241	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—IL6—multiple sclerosis	1.44e-05	0.000241	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—IL6—multiple sclerosis	1.43e-05	0.000238	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HLA-DRB1—multiple sclerosis	1.42e-05	0.000237	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—IL6—multiple sclerosis	1.42e-05	0.000237	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—STAT3—multiple sclerosis	1.42e-05	0.000237	CbGpPWpGaD
Lidocaine—EGFR—Disease—CD28—multiple sclerosis	1.41e-05	0.000236	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—STAT3—multiple sclerosis	1.4e-05	0.000234	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ITGA4—multiple sclerosis	1.4e-05	0.000233	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD40—multiple sclerosis	1.4e-05	0.000233	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—IL6—multiple sclerosis	1.39e-05	0.000232	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IFNB1—multiple sclerosis	1.39e-05	0.000232	CbGpPWpGaD
Lidocaine—CYP1A2—Biological oxidations—POMC—multiple sclerosis	1.38e-05	0.00023	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GPC5—multiple sclerosis	1.38e-05	0.00023	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CTLA4—multiple sclerosis	1.38e-05	0.00023	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—IL6—multiple sclerosis	1.37e-05	0.000229	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—CD80—multiple sclerosis	1.37e-05	0.000228	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CXCL10—multiple sclerosis	1.37e-05	0.000228	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—ICAM1—multiple sclerosis	1.37e-05	0.000228	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—RRM1—multiple sclerosis	1.35e-05	0.000225	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—RRM1—multiple sclerosis	1.32e-05	0.00022	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CD80—multiple sclerosis	1.31e-05	0.000219	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP27B1—multiple sclerosis	1.31e-05	0.000219	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP24A1—multiple sclerosis	1.31e-05	0.000219	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—TYK2—multiple sclerosis	1.31e-05	0.000218	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—TGFB1—multiple sclerosis	1.3e-05	0.000216	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—MAPK1—multiple sclerosis	1.29e-05	0.000215	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	1.29e-05	0.000215	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—MAPK1—multiple sclerosis	1.27e-05	0.000212	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.24e-05	0.000208	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.24e-05	0.000207	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.24e-05	0.000207	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	1.23e-05	0.000205	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	1.23e-05	0.000205	CbGpPWpGaD
Lidocaine—EGFR—Immune System—VCAM1—multiple sclerosis	1.22e-05	0.000203	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-DQA1—multiple sclerosis	1.21e-05	0.000203	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—TNF—multiple sclerosis	1.21e-05	0.000202	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GPC5—multiple sclerosis	1.2e-05	0.000201	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.2e-05	0.0002	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CCL5—multiple sclerosis	1.18e-05	0.000197	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—MAPK1—multiple sclerosis	1.17e-05	0.000195	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—TYK2—multiple sclerosis	1.16e-05	0.000193	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SRM—multiple sclerosis	1.15e-05	0.000192	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—RRM1—multiple sclerosis	1.14e-05	0.000191	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-DQB1—multiple sclerosis	1.13e-05	0.000189	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.13e-05	0.000189	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.12e-05	0.000187	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD86—multiple sclerosis	1.09e-05	0.000182	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCL3—multiple sclerosis	1.07e-05	0.000179	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD40LG—multiple sclerosis	1.07e-05	0.000179	CbGpPWpGaD
Lidocaine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.06e-05	0.000178	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CCR5—multiple sclerosis	1.06e-05	0.000177	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD8A—multiple sclerosis	1.06e-05	0.000177	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.05e-05	0.000175	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.05e-05	0.000175	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.05e-05	0.000175	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL2RA—multiple sclerosis	1.05e-05	0.000174	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—CD4—multiple sclerosis	1.04e-05	0.000174	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTGER4—multiple sclerosis	1.03e-05	0.000173	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—MMP9—multiple sclerosis	1.03e-05	0.000172	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.03e-05	0.000171	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-B—multiple sclerosis	1.02e-05	0.00017	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PGR—multiple sclerosis	1.02e-05	0.00017	CbGpPWpGaD
Lidocaine—EGFR—Disease—CD86—multiple sclerosis	1.01e-05	0.000168	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CD4—multiple sclerosis	1e-05	0.000167	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCR3—multiple sclerosis	9.99e-06	0.000167	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—RRM1—multiple sclerosis	9.96e-06	0.000166	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—IL6—multiple sclerosis	9.91e-06	0.000165	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CD28—multiple sclerosis	9.9e-06	0.000165	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—IL6—multiple sclerosis	9.77e-06	0.000163	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCR2—multiple sclerosis	9.72e-06	0.000162	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—BCHE—multiple sclerosis	9.61e-06	0.00016	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GPC5—multiple sclerosis	9.59e-06	0.00016	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL2RA—multiple sclerosis	9.55e-06	0.000159	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—APOE—multiple sclerosis	9.49e-06	0.000158	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-A—multiple sclerosis	9.44e-06	0.000158	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—RRM1—multiple sclerosis	9.38e-06	0.000157	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—RRM1—multiple sclerosis	9.3e-06	0.000155	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	9.19e-06	0.000153	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	9.16e-06	0.000153	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—STAT3—multiple sclerosis	9.16e-06	0.000153	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	8.99e-06	0.00015	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CNR1—multiple sclerosis	8.97e-06	0.00015	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—IL6—multiple sclerosis	8.96e-06	0.00015	CbGpPWpGaD
Lidocaine—EGFR—Disease—CCR5—multiple sclerosis	8.95e-06	0.000149	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.87e-06	0.000148	CbGpPWpGaD
Lidocaine—EGFR—Disease—HLA-A—multiple sclerosis	8.72e-06	0.000146	CbGpPWpGaD
Lidocaine—EGFR—Immune System—TLR4—multiple sclerosis	8.64e-06	0.000144	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-DRB1—multiple sclerosis	8.63e-06	0.000144	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	8.56e-06	0.000143	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—TGFB1—multiple sclerosis	8.49e-06	0.000142	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—MAPK1—multiple sclerosis	8.33e-06	0.000139	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—POMC—multiple sclerosis	8.29e-06	0.000138	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ICAM1—multiple sclerosis	8.28e-06	0.000138	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—POMC—multiple sclerosis	8.15e-06	0.000136	CbGpPWpGaD
Lidocaine—EGFR—Disease—APOE—multiple sclerosis	8.14e-06	0.000136	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CCL2—multiple sclerosis	8.11e-06	0.000135	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	8.09e-06	0.000135	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	8.09e-06	0.000135	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCL10—multiple sclerosis	8.08e-06	0.000135	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD80—multiple sclerosis	7.97e-06	0.000133	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—RRM1—multiple sclerosis	7.95e-06	0.000133	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—TNF—multiple sclerosis	7.93e-06	0.000132	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—BCHE—multiple sclerosis	7.75e-06	0.000129	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.62e-06	0.000127	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—BCHE—multiple sclerosis	7.58e-06	0.000127	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—ALB—multiple sclerosis	7.43e-06	0.000124	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GPC5—multiple sclerosis	7.4e-06	0.000124	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—TYK2—multiple sclerosis	7.36e-06	0.000123	CbGpPWpGaD
Lidocaine—EGFR—Disease—CD80—multiple sclerosis	7.36e-06	0.000123	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—MAPK1—multiple sclerosis	7.35e-06	0.000123	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.22e-06	0.00012	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CD86—multiple sclerosis	7.06e-06	0.000118	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCL5—multiple sclerosis	6.95e-06	0.000116	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.94e-06	0.000116	CbGpPWpGaD
Lidocaine—EGFR—Immune System—TYK2—multiple sclerosis	6.73e-06	0.000112	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—BCHE—multiple sclerosis	6.56e-06	0.00011	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SPP1—multiple sclerosis	6.44e-06	0.000108	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—IL6—multiple sclerosis	6.4e-06	0.000107	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—APOE—multiple sclerosis	6.31e-06	0.000105	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IFNG—multiple sclerosis	6.3e-06	0.000105	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCR5—multiple sclerosis	6.26e-06	0.000105	CbGpPWpGaD
Lidocaine—EGFR—Disease—TYK2—multiple sclerosis	6.21e-06	0.000104	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.2e-06	0.000104	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL2RA—multiple sclerosis	6.17e-06	0.000103	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.17e-06	0.000103	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—RRM1—multiple sclerosis	6.13e-06	0.000102	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL2—multiple sclerosis	6.13e-06	0.000102	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD4—multiple sclerosis	6.08e-06	0.000102	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—APOE—multiple sclerosis	5.78e-06	9.65e-05	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	5.75e-06	9.61e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—BCHE—multiple sclerosis	5.72e-06	9.55e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—APOE—multiple sclerosis	5.7e-06	9.52e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.65e-06	9.44e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—IL6—multiple sclerosis	5.65e-06	9.43e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL1B—multiple sclerosis	5.62e-06	9.38e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CD4—multiple sclerosis	5.62e-06	9.38e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL2—multiple sclerosis	5.6e-06	9.35e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—POMC—multiple sclerosis	5.42e-06	9.05e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—BCHE—multiple sclerosis	5.39e-06	9e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—BCHE—multiple sclerosis	5.34e-06	8.92e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.3e-06	8.85e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CD80—multiple sclerosis	5.15e-06	8.6e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—POMC—multiple sclerosis	4.97e-06	8.29e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ALB—multiple sclerosis	4.94e-06	8.25e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—POMC—multiple sclerosis	4.9e-06	8.17e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.83e-06	8.06e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCL2—multiple sclerosis	4.79e-06	8e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—STAT3—multiple sclerosis	4.71e-06	7.87e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—MAPK1—multiple sclerosis	4.69e-06	7.83e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—APOE—multiple sclerosis	4.66e-06	7.79e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—BCHE—multiple sclerosis	4.57e-06	7.62e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—APOE—multiple sclerosis	4.56e-06	7.61e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ALB—multiple sclerosis	4.53e-06	7.56e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TYK2—multiple sclerosis	4.35e-06	7.26e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—STAT3—multiple sclerosis	4.35e-06	7.26e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MAPK1—multiple sclerosis	4.28e-06	7.15e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MYC—multiple sclerosis	4.04e-06	6.75e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—TGFB1—multiple sclerosis	4.03e-06	6.73e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—POMC—multiple sclerosis	4.01e-06	6.69e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MAPK1—multiple sclerosis	3.95e-06	6.6e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—APOE—multiple sclerosis	3.95e-06	6.59e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—POMC—multiple sclerosis	3.92e-06	6.54e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ALB—multiple sclerosis	3.65e-06	6.1e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL2—multiple sclerosis	3.62e-06	6.04e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL6—multiple sclerosis	3.6e-06	6.01e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ALB—multiple sclerosis	3.57e-06	5.96e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.52e-06	5.88e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—APOE—multiple sclerosis	3.44e-06	5.74e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MMP9—multiple sclerosis	3.43e-06	5.72e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—POMC—multiple sclerosis	3.39e-06	5.66e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL6—multiple sclerosis	3.29e-06	5.49e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—APOE—multiple sclerosis	3.24e-06	5.41e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—APOE—multiple sclerosis	3.21e-06	5.37e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ALB—multiple sclerosis	3.09e-06	5.16e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—STAT3—multiple sclerosis	3.05e-06	5.09e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—IL6—multiple sclerosis	3.04e-06	5.07e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—POMC—multiple sclerosis	2.96e-06	4.93e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MYC—multiple sclerosis	2.83e-06	4.73e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TGFB1—multiple sclerosis	2.82e-06	4.71e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—POMC—multiple sclerosis	2.78e-06	4.65e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MAPK1—multiple sclerosis	2.77e-06	4.62e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—POMC—multiple sclerosis	2.76e-06	4.61e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—APOE—multiple sclerosis	2.75e-06	4.59e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ALB—multiple sclerosis	2.69e-06	4.5e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ALB—multiple sclerosis	2.54e-06	4.24e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ALB—multiple sclerosis	2.52e-06	4.2e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—POMC—multiple sclerosis	2.36e-06	3.94e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ALB—multiple sclerosis	2.15e-06	3.59e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL6—multiple sclerosis	2.13e-06	3.55e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—APOE—multiple sclerosis	2.12e-06	3.54e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—POMC—multiple sclerosis	1.82e-06	3.04e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALB—multiple sclerosis	1.66e-06	2.77e-05	CbGpPWpGaD
